LFG
DSGN icon

Larson Financial Group’s Design Therapeutics DSGN Stock Holding History

Larson Financial Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62K Hold
181
– – ﹤0.01% 3036
2026
Q1 		$1.93K Buy
181
+178
+5,933% +$1.8K ﹤0.01% 2966
2025
Q4 		$28 Hold
3
– – ﹤0.01% 3405
2025
Q3 		$23 Buy
+3
New +$15 ﹤0.01% 3390

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Larson Financial Group's DSGN Position: Q2 2026 in Review

Larson Financial Group held its Design Therapeutics (DSGN) position steady in Q2 2026 at 181 shares worth $2.62K. The position accounts for ﹤0.01% of the portfolio, ranked #3036.

Larson Financial Group first reported a position in DSGN in Q3 2025 and has held it in 4 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Larson Financial Group held 181 shares of Design Therapeutics worth $2.62K as of Q2 2026.
  • Larson Financial Group left its Design Therapeutics share count unchanged in Q2 2026.
  • Design Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3036 holding.
  • Larson Financial Group first reported a position in Design Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.